It’s been quite a year for Akcea Therapeutics (AKCA). After going public in July 2017, the Cambridge, Mass., company almost immediately filed for FDA approval on two drugs for rare diseases.

Volanesorsen, also known as Waylivra, is intended to treat familial chylomicronemia syndrome (FCS), a condition that leads to a buildup of fat in organs. Inotersen, which has the brand name Tegsedi, treats hereditary transthyretin amyloidosis, known as hATTR for short. The condition leads to a buildup of proteins that can cause issues in the nerves and heart. European authorities have already approved inotersen, and the FDA is set to decide on both those drugs before the end of the year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Excellent commentary.
    Hope that both innovative products succeed by
    having a fairly even physician/ patient preference,
    if they can’t be differentiated in any other way.

    CEO should ideally always be diversity neutral;
    just need the best person available to do a job well.

    • Diversities naturally 8 which politician want to lose himself also don’t want to get down money rates if they don’t continue so soon lose all because if somebody take Africa market so and mark its all money come back and that countries so that time is very horrible I think so

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy